A new era of genetic engineering for autoimmune and inflammatory diseases

Research output: Contribution to journalReview article

Abstract

Chronic autoimmune and inflammatory diseases exhibit variable genetic factors. The tools for specific and efficient genetic engineering are developing at a dramatic pace and are now being applied to therapy of human diseases. Gene editing tools can be used to interdict the pathology of inflammation at multiple stages. Therapies utilizing genetically modified cells offer many potential advantages over traditional cellular therapy approaches. Monogenic autoinflammatory disease, loss of self-tolerance, autoimmune disease based in humoral immunity, and regenerative medicine for tissues deranged or destroyed by inflammation are potential pathologies that could be treated with therapies based in genetic editing technologies. In this review, we discuss the rapid evolution of technologies for genome editing and their applications for autoimmune and inflammatory diseases. We compare older-generation methods, including zinc-finger nucleases and transcription activator-like effector nucleases, with more-recently developed tools, mainly CRISPR/Cas9. Gene-editing tool delivery methods including viral vectors and non-viral technologies are summarized. Finally, pre-clinical experiments with gene editing for therapy of animal models of autoimmune and inflammatory disease, and initial experience with gene-edited cells in human autoimmunity are described. In this review, we discuss potential therapeutic uses of chimeric autoantigen receptor T cells and regulatory T cells for polygenic disease, genetically-modified hematopoietic stem and progenitor cell transplantation for monogenic disease, and modified induced pluripotent stem cells for regenerative medicine.

Original languageEnglish (US)
Pages (from-to)e1-e7
JournalSeminars in Arthritis and Rheumatism
Volume49
Issue number1
DOIs
StatePublished - Aug 1 2019

Fingerprint

Genetic Engineering
Autoimmune Diseases
Regenerative Medicine
Technology
Clustered Regularly Interspaced Short Palindromic Repeats
Pathology
Inflammation
Self Tolerance
Induced Pluripotent Stem Cells
Hematopoietic Stem Cell Transplantation
Zinc Fingers
Autoantigens
Therapeutic Uses
Regulatory T-Lymphocytes
Therapeutics
Humoral Immunity
Hematopoietic Stem Cells
T-Cell Antigen Receptor
Autoimmunity
Genetic Therapy

Keywords

  • Autoimmune diseases
  • Autoimmunity
  • Gene editing
  • Inflammation

PubMed: MeSH publication types

  • Journal Article
  • Review

Cite this

A new era of genetic engineering for autoimmune and inflammatory diseases. / Ewart, Dave; Peterson, Erik J; Steer, Clifford J.

In: Seminars in Arthritis and Rheumatism, Vol. 49, No. 1, 01.08.2019, p. e1-e7.

Research output: Contribution to journalReview article

@article{c36e53b9177944bf89aeb643072a79ab,
title = "A new era of genetic engineering for autoimmune and inflammatory diseases",
abstract = "Chronic autoimmune and inflammatory diseases exhibit variable genetic factors. The tools for specific and efficient genetic engineering are developing at a dramatic pace and are now being applied to therapy of human diseases. Gene editing tools can be used to interdict the pathology of inflammation at multiple stages. Therapies utilizing genetically modified cells offer many potential advantages over traditional cellular therapy approaches. Monogenic autoinflammatory disease, loss of self-tolerance, autoimmune disease based in humoral immunity, and regenerative medicine for tissues deranged or destroyed by inflammation are potential pathologies that could be treated with therapies based in genetic editing technologies. In this review, we discuss the rapid evolution of technologies for genome editing and their applications for autoimmune and inflammatory diseases. We compare older-generation methods, including zinc-finger nucleases and transcription activator-like effector nucleases, with more-recently developed tools, mainly CRISPR/Cas9. Gene-editing tool delivery methods including viral vectors and non-viral technologies are summarized. Finally, pre-clinical experiments with gene editing for therapy of animal models of autoimmune and inflammatory disease, and initial experience with gene-edited cells in human autoimmunity are described. In this review, we discuss potential therapeutic uses of chimeric autoantigen receptor T cells and regulatory T cells for polygenic disease, genetically-modified hematopoietic stem and progenitor cell transplantation for monogenic disease, and modified induced pluripotent stem cells for regenerative medicine.",
keywords = "Autoimmune diseases, Autoimmunity, Gene editing, Inflammation",
author = "Dave Ewart and Peterson, {Erik J} and Steer, {Clifford J}",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.semarthrit.2019.05.004",
language = "English (US)",
volume = "49",
pages = "e1--e7",
journal = "Seminars in Arthritis and Rheumatism",
issn = "0049-0172",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - A new era of genetic engineering for autoimmune and inflammatory diseases

AU - Ewart, Dave

AU - Peterson, Erik J

AU - Steer, Clifford J

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Chronic autoimmune and inflammatory diseases exhibit variable genetic factors. The tools for specific and efficient genetic engineering are developing at a dramatic pace and are now being applied to therapy of human diseases. Gene editing tools can be used to interdict the pathology of inflammation at multiple stages. Therapies utilizing genetically modified cells offer many potential advantages over traditional cellular therapy approaches. Monogenic autoinflammatory disease, loss of self-tolerance, autoimmune disease based in humoral immunity, and regenerative medicine for tissues deranged or destroyed by inflammation are potential pathologies that could be treated with therapies based in genetic editing technologies. In this review, we discuss the rapid evolution of technologies for genome editing and their applications for autoimmune and inflammatory diseases. We compare older-generation methods, including zinc-finger nucleases and transcription activator-like effector nucleases, with more-recently developed tools, mainly CRISPR/Cas9. Gene-editing tool delivery methods including viral vectors and non-viral technologies are summarized. Finally, pre-clinical experiments with gene editing for therapy of animal models of autoimmune and inflammatory disease, and initial experience with gene-edited cells in human autoimmunity are described. In this review, we discuss potential therapeutic uses of chimeric autoantigen receptor T cells and regulatory T cells for polygenic disease, genetically-modified hematopoietic stem and progenitor cell transplantation for monogenic disease, and modified induced pluripotent stem cells for regenerative medicine.

AB - Chronic autoimmune and inflammatory diseases exhibit variable genetic factors. The tools for specific and efficient genetic engineering are developing at a dramatic pace and are now being applied to therapy of human diseases. Gene editing tools can be used to interdict the pathology of inflammation at multiple stages. Therapies utilizing genetically modified cells offer many potential advantages over traditional cellular therapy approaches. Monogenic autoinflammatory disease, loss of self-tolerance, autoimmune disease based in humoral immunity, and regenerative medicine for tissues deranged or destroyed by inflammation are potential pathologies that could be treated with therapies based in genetic editing technologies. In this review, we discuss the rapid evolution of technologies for genome editing and their applications for autoimmune and inflammatory diseases. We compare older-generation methods, including zinc-finger nucleases and transcription activator-like effector nucleases, with more-recently developed tools, mainly CRISPR/Cas9. Gene-editing tool delivery methods including viral vectors and non-viral technologies are summarized. Finally, pre-clinical experiments with gene editing for therapy of animal models of autoimmune and inflammatory disease, and initial experience with gene-edited cells in human autoimmunity are described. In this review, we discuss potential therapeutic uses of chimeric autoantigen receptor T cells and regulatory T cells for polygenic disease, genetically-modified hematopoietic stem and progenitor cell transplantation for monogenic disease, and modified induced pluripotent stem cells for regenerative medicine.

KW - Autoimmune diseases

KW - Autoimmunity

KW - Gene editing

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=85066078940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066078940&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2019.05.004

DO - 10.1016/j.semarthrit.2019.05.004

M3 - Review article

VL - 49

SP - e1-e7

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 1

ER -